Sunday, April 4, 2010
RESULTS FROM THE FIRST PHASE I CLINICAL STUDY OF THE NOVEL II-KEY/HER-2/NEU (776–790) HYBRID PEPTIDE VACCINE IN PATIENTS WITH PROSTATE CANCER
European Urology Supplements publishes peer-reviewed original articles and topical reviews on a wide range of urological problems. Topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, as well as recent advances in techniques, instrumentation, surgery and pediatric urology provide readers with a complete guide to international developments in urology.
Current Edition- April 2010
950 RESULTS FROM THE FIRST PHASE I CLINICAL STUDY OF THE NOVEL II-KEY/HER-2/NEU (776–790) HYBRID PEPTIDE VACCINE IN PATIENTS WITH PROSTATE CANCER
These results are more expansive than what was reported at during a podium presentation at ASCO 2009. Read the latest results here.
Once again, the AE37 HER2/NEU hybrid peptide vaccine has very limited toxicity, with no patients experiencing toxicity over Grade 2. That is a very important advantage, since most cancer drugs are hard to tolerate. The efficacy of AE37 is even more impressive, as the report details a lowering of PSA levels for most patients with a majority experiencing a DTH response, which in turn leads to vastly improved medium progression free survival (18 months to 1 month) for DTH responders.
Perhaps we get an update at the upcoming 25th Annual EAU Congress in Barcelona. At the EAU 2010 website, this AE37 Phase I study in patients with prostate cancer is slated for a poster presentation on Monday, 19 April 2010. Under session "Focal and systemic therapies", I found Dr T.K. Karaolides from Saint Savas Cancer Hospital in Athens is listed as the speaker. You can view the abstract titles from that session here.